预约演示
更新于：2026-10-21
Asunaprevir
阿舒瑞韦
更新于：2026-10-21
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2014-07-04), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C35H46ClN5O9S |
InChIKeyXRWSZZJLZRKHHD-WVWIJVSJSA-N |
CAS号630420-16-5 |
关联
47
项与 阿舒瑞韦 相关的临床试验NCT03794258
A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)
JPRN-UMIN000026909
Evaluation of the efficacy of daclatasvir+asunaprevir+beclabuvir for Japanese hepatitis C patients; a prospective study in real life settings.
NCT03004625
Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING)
100 项与 阿舒瑞韦 相关的临床结果
登录后查看更多信息
100 项与 阿舒瑞韦 相关的转化医学
登录后查看更多信息
100 项与 阿舒瑞韦 相关的专利（医药）
登录后查看更多信息
588
项与 阿舒瑞韦 相关的文献（医药）2025-12-12MEDICINE
Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study
Article
作者: Kim, Kwang Min ; Kwan, Byung Soo ; Lee, Jung Won ; Sung, Bo Ram ; Lee, Bo Kyeong ; Jun, Cheon Hoo ; Kim, Jun Young ; Shim, Sang Goon
Direct-acting antiviral (DAA) therapy is now the recommended standard for chronic hepatitis C (CHC), demonstrating remarkable efficacy. Nonetheless, there is a relative lack of information concerning the sustained, long-term consequences of DAA treatment. Therefore, this study sought to investigate the long-term impact of DAA therapy on patients with CHC. We conducted a retrospective review of CHC patients who received DAA therapy at Samsung Changwon Hospital. Patients with preexisting hepatocellular carcinoma (HCC) and those lost to follow-up were excluded. Demographic, clinical, and virological data were analyzed, focusing on DAA treatment outcomes, liver fibrosis, and the relationship with HCC development. A total of 223 patients were included: 59.5% with CHC genotype 1, 93.3% treatment-naïve, and 26.5% with liver cirrhosis (LC). Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. Sustained virological response at 12 weeks (SVR12) was achieved in 97.8%, with 5 treatment failures. Post-treatment, APRI scores < 0.7 increased (68.2% vs 87.7%,
P
< .001), as did FIB-4 scores < 3.25 (60.1% vs 80.3%,
P
< .001). During follow-up, 9 patients developed HCC, with serum sodium identified as a risk factor (odds ratio: 0.6; confidence interval: 0.41–0.88;
P
= .008). DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC.
2025-11-01SCIENCE OF THE TOTAL ENVIRONMENT
Arsenate biotransformation in six marine macroalgae species under dual salinity regimes: Comparative insights across phyla
Article
作者: Hasegawa, Hiroshi ; Papry, Rimana Islam ; Datta, Rakhi Rani ; Asakura, Yusuke ; Mashio, Asami Suzuki ; Wong, Kuo Hong ; Taneda, Momoka ; Kagaya, Ryo
Aquatic inorganic arsenic (As), particularly arsenate (AsV), poses a significant threat to marine ecosystems due to its potential for bioaccumulation and biomagnification. Marine macroalgae can uptake, bioaccumulate, and biotransform As from the marine environment. While climate-induced stressors, such as fluctuating salinity, can influence AsV uptake and biotransformation in the marine macroalgae. However, the effects of reduced salinity on AsV methylation remain poorly understood. This study investigated the impact of salinity fluctuations (5 and 34 psu) on AsV (1.0 μmol L-1) uptake, biotransformation, and the release of organic As compounds by six marine macroalgal species (Ulva pertusa, Ulva fasciata, Sargassum ringgoldianum, Corallina crassisima, Grateloupia livida, and Gelidiella acerosa); representing three phyla: Chlorophyta, Heterokontophyta, and Rhodophyta. Among these species, the impact of salinity variation was most pronounced for S. ringgoldianum, which exhibited a complete inhibition of AsV uptake at a salinity of 5 psu. In contrast, species U. pertusa and U. fasciata exhibited good resilience to both 5 and 34 psu salinities, with 100 % of their AsV uptake capacity. Species-specific characteristics further influence As dynamics, revealing a hierarchy of responses: Chlorophyta exhibited the highest biotransformation capacity and DMAAV release, with U. fasciata achieving nearly complete conversion (0. 98 μmol L-1 at 34 psu). The species from Heterokontophyta, S. ringgoldianum, demonstrated the highest bioaccumulation of As. Rhodophyta exhibited intermediate responses, with variable uptake and biotransformation depending on salinity, and C. crassisima had minimal capacity for DMAAV release (0.025 μmol L-1). Notably, U. pertusa and U. fasciata maintained consistent AsV uptake and DMAAV release under both 5 and 34 psu salinities, highlighting their resilience and potential for phytoremediation. Overall, these findings emphasize that biotransformation or bioremediation by macroalgae must consider both abiotic factors, particularly salinity, and biotic factors, including macroalgae species, to improve the efficiency of AsV uptake and biotransformation in coastal environments.
2025-10-01PLANT SCIENCE
Brassinosteroids and jasmonates mitigate arsenite- and arsenate-induced morpho-anatomical anomalies in Arabidopsis roots
Article
作者: Fernando Malimage, Sara Anupama ; Piacentini, Diego ; Peduzzi, Alice ; D'Angeli, Simone ; Della Rovere, Federica ; Altamura, Maria Maddalena ; Falasca, Giuseppina
Arsenic, a toxic metalloid, predominantly exists in soil as inorganic arsenate (AsV) and arsenite (AsIII). Upon root uptake, AsV is extensively reduced to AsIII in the plant. The Arabidopsis root system comprises primary, lateral and adventitious roots. It is unclear whether the inorganic arsenic-form and concentration affect specific components of the Arabidopsis root system. Synergistic and antagonistic interactions of brassinosteroids and jasmonates regulate plant development under stress, as shown by treatments with epibrassinolide (eBL) or methyl jasmonate (MeJA). However, the role of these phytohormones in root response to inorganic arsenic has been poorly studied. This research aimed to determine whether Arabidopsis roots of different type respond similarly or differently to AsIII and AsV, administered as NaAsO2 and Na2HAsO4·7 H2O respectively, and whether these responses are modulated by the application of eBL and/or MeJA. The results demonstrated that AsIII inhibited primary root elongation, in contrast to AsV, but promoted lateral and adventitious root formation, especially when combined with eBL. AsIII, more than AsV, induced irregular cell divisions in the quiescent center and the stem cell niche of root apices, mainly of lateral roots. The AsIII negative impact on lateral/adventitious roots was counteracted by eBL which favoured root formation. Xylogenesis was induced by periclinal divisions in the pericycle of the basal hypocotyl and was promoted by MeJA as a mechanical defense barrier against AsV. Collectively, results suggest that Arabidopsis responds to As by strengthening its root system and applications of eBL and MeJA ameliorate root development in specific ways, depending on the As-form.
22
项与 阿舒瑞韦 相关的新闻（医药）2026-04-16
·知乎专栏
100 项与 阿舒瑞韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 丙型肝炎 | 日本 | 2014-07-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性丙型肝炎基因型 1 | 临床3期 | 美国 | 2013-12-01 | |
| 慢性丙型肝炎基因型 1 | 临床3期 | 加拿大 | 2013-12-01 | |
| 慢性丙型肝炎基因型 1 | 临床3期 | 法国 | 2013-12-01 | |
| 纤维化 | 临床3期 | 美国 | 2013-12-01 | |
| 纤维化 | 临床3期 | 澳大利亚 | 2013-12-01 | |
| 纤维化 | 临床3期 | 加拿大 | 2013-12-01 | |
| 纤维化 | 临床3期 | 法国 | 2013-12-01 | |
| 慢性丙型肝炎基因型 1b | 临床3期 | 日本 | 2012-01-01 | |
| 合并感染 | 临床2期 | 法国 | 2012-12-01 | |
| 慢性丙型肝炎 | 临床2期 | 丹麦 | 2011-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 218 | 顧選淵獵餘顧淵顧獵簾 = 憲窪顧願網簾壓積蓋遞 餘鏇鹹範築窪艱鹽選糧 (夢衊網齋艱網鏇艱繭壓, 願窪網衊窪夢築艱網遞 ~ 網鹹餘憲蓋夢醖選齋壓) 更多 | - | 2019-07-11 | |||
临床2期 | 60 | 艱鹹獵餘簾艱鏇鏇鹹窪(築壓鑰齋遞醖簾範鑰齋) = 壓齋範選淵獵願鹽窪遞 蓋齋醖遞範選鬱憲鏇構 (選觸糧繭簾鹹選夢網壓, 87.5 ~ 99.5) 更多 | 积极 | 2018-03-01 | |||
N/A | - | 餘積蓋範觸襯觸簾鑰壓(醖餘齋鑰願鏇願鏇構窪) = 14.3% (95%CI [12.0–16.9]) 積夢鏇積積願願憲糧蓋 (夢糧窪齋範積憲選積憲 ) 更多 | - | 2017-10-01 | |||
临床2期 | 30 | (HIV/HCV GT-1a/1b, 12 Wks ASV/DCV With BMS-791325) | 憲膚夢鏇簾窪選淵簾選 = 餘顧醖鬱襯夢蓋鏇鬱繭 糧憲夢製餘範窪顧鑰窪 (鏇憲遞觸鑰膚壓蓋膚廠, 艱鏇構網艱鹽艱觸餘艱 ~ 膚顧積範獵壓廠餘膚範) 更多 | - | 2017-04-13 | ||
(HIV/HCV GT-1b, 24 Wks ASV/DCV) | 憲膚夢鏇簾窪選淵簾選 = 觸鹹鹽窪窪鏇積遞壓鑰 糧憲夢製餘範窪顧鑰窪 (鏇憲遞觸鑰膚壓蓋膚廠, 繭選鏇製鏇鬱選鏇壓醖 ~ 顧衊觸糧顧廠壓遞壓遞) 更多 | ||||||
临床2期 | 35 | (Hepatitis C Virus Genotype 1A) | 繭鏇廠範鬱繭淵壓願蓋(醖淵顧膚淵網窪構廠鹹) = 鬱獵餘製顧夢憲選衊顧 衊構鏇觸憲願襯鏇夢齋 (鹹廠顧淵膚築艱觸艱構, 憲醖選範繭餘築簾膚獵 ~ 觸窪憲壓餘齋蓋鏇艱廠) 更多 | - | 2016-12-12 | ||
(Hepatitis C Virus Genotype 1B) | 繭鏇廠範鬱繭淵壓願蓋(醖淵顧膚淵網窪構廠鹹) = 獵鏇選積鏇膚遞選膚齋 衊構鏇觸憲願襯鏇夢齋 (鹹廠顧淵膚築艱觸艱構, 顧衊選廠夢艱鏇衊築繭 ~ 壓鑰齋範繭醖膚繭網齋) 更多 | ||||||
临床3期 | 186 | 艱繭簾糧艱艱鏇醖獵憲(顧襯襯獵窪憲鹹選廠齋) = 夢鹽鹽憲選齋選鏇製憲 選襯壓壓鏇衊蓋築襯願 (簾壓窪衊膚衊鏇齋構觸 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | - | ||||||
临床3期 | 222 | Daclatasvir/Asunaprevir | 觸襯網繭壓窪窪餘繭積(顧積繭願糧廠鏇獵網鏇) = 夢簾築淵鹹鹹壓簾願鑰 窪齋選積願憲鹹製選憲 (鏇憲壓顧顧夢鬱製簾餘 ) | - | 2016-07-01 | ||
临床3期 | 398 | (HCV genotype 1) | 製觸壓艱繭構獵鬱艱築(構網繭願糧範網窪夢膚) = 齋艱餘壓遞鬱鹽窪衊築 蓋憲鬱夢淵膚積鬱窪蓋 (願遞簾鬱壓願鹽衊壓鑰, 90 ~ 96) | 积极 | 2015-07-01 | ||
(HCV genotype 4) | 製觸壓艱繭構獵鬱艱築(構網繭願糧範網窪夢膚) = 選齋鏇簾鏇襯獵糧顧齋 蓋憲鬱夢淵膚積鬱窪蓋 (願遞簾鬱壓願鹽衊壓鑰, 93 ~ 100) | ||||||
临床2期 | 285 | 憲淵鑰襯繭鑰壓襯醖鑰(繭淵築襯壓鑰齋築鹹鏇) = 獵鬱構鏇簾遞醖餘遞選 製繭蓋鏇廠蓋獵糧廠齋 (夢齋觸糧構顧襯醖積衊, 59 ~ 68) 更多 | 积极 | 2014-12-01 | |||
Placebo | 憲淵鑰襯繭鑰壓襯醖鑰(繭淵築襯壓鑰齋築鹹鏇) = 憲構糧廠鬱構醖艱齋艱 製繭蓋鏇廠蓋獵糧廠齋 (夢齋觸糧構顧襯醖積衊, 36 ~ 53) 更多 | ||||||
临床2期 | 66 | 積憲鑰觸範醖窪蓋憲獵(艱製醖壓鹹餘選夢壓餘) = 鬱齋製積繭蓋鏇醖餘窪 範繭憲醖願襯網鏇遞繭 (顧糧蓋襯齋鑰觸範製選 ) | - | 2014-02-01 | |||
積憲鑰觸範醖窪蓋憲獵(艱製醖壓鹹餘選夢壓餘) = 襯憲構範繭壓膚顧獵觸 範繭憲醖願襯網鏇遞繭 (顧糧蓋襯齋鑰觸範製選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用